DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “buy” rating restated by stock analysts at Leerink Swann in a research note issued to investors on Friday. They presently have a $57.00 target price on the medical device company’s stock. Leerink Swann’s target price points to a potential upside of 16.50% from the stock’s current price. Leerink Swann also issued estimates for DexCom’s Q4 2018 earnings at $0.00 EPS and FY2021 earnings at $0.78 EPS.

Several other analysts have also weighed in on the company. Raymond James Financial, Inc. lowered DexCom from an “outperform” rating to a “mkt perform” rating in a report on Friday. ValuEngine lowered DexCom from a “hold” rating to a “sell” rating in a report on Thursday. Piper Jaffray Companies restated a “buy” rating and issued a $87.00 price objective on shares of DexCom in a report on Thursday. Stephens restated a “buy” rating and issued a $70.00 price objective (down previously from $83.00) on shares of DexCom in a report on Thursday. Finally, Barclays PLC restated an “equal weight” rating and issued a $60.00 price objective (down previously from $76.00) on shares of DexCom in a report on Thursday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. DexCom currently has an average rating of “Buy” and a consensus price target of $72.19.

DexCom (NASDAQ:DXCM) opened at 48.925 on Friday. DexCom has a 1-year low of $45.61 and a 1-year high of $94.24. The firm’s market cap is $4.23 billion. The stock’s 50 day moving average price is $72.62 and its 200 day moving average price is $73.86.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. During the same quarter in the prior year, the business posted ($0.24) earnings per share. The company’s revenue for the quarter was up 24.3% compared to the same quarter last year. Equities research analysts predict that DexCom will post ($0.79) EPS for the current year.

TRADEMARK VIOLATION WARNING: “DexCom, Inc. (DXCM) Rating Reiterated by Leerink Swann” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/dexcom-inc-dxcm-rating-reiterated-by-leerink-swann/1600697.html.

In related news, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $71.55, for a total value of $228,960.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $69.47, for a total value of $100,731.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,223 shares of company stock valued at $2,285,138. Company insiders own 1.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Advisor Group Inc. lifted its stake in DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after acquiring an additional 837 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in DexCom in the 1st quarter worth about $164,000. Brighton Jones LLC purchased a new stake in DexCom in the 1st quarter worth about $204,000. IFP Advisors Inc lifted its stake in DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after acquiring an additional 568 shares in the last quarter. Finally, Independent Portfolio Consultants Inc. lifted its stake in DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after acquiring an additional 9 shares in the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.